Tech Company M&A Transactions
Cequent Pharmaceuticals Acquisition
Headquartered in Cambridge, Cequent Pharmaceuticals was acquired by Marina Biotech. Marina Biotech disclosed that the acquisition price was $46 million.
Transaction Overview
Company Name
Acquired By
Announced On
4/1/2010
Transaction Type
M&A
Amount
$46,000,000
M&A Terms
MDRNA will acquire Cequent Pharmaceuticals in an all-stock deal worth $46 million.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
1 Kendall Sq. Building 700 First Floor
Cambridge, MA 02139
USA
Cambridge, MA 02139
USA
Phone
Website
Email Address
Overview
Cequent Pharmaceuticals, Inc. is an early-stage biopharmaceutical company developing new clinically compatible therapies based on RNA interference (RNAi). Cequent is focusing its efforts on the pre-clinical development of products to treat gastrointestinal diseases, including familial polyposis, inflammatory bowel disease and colon cancer.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Peter Parker
Chief Financial Officer
Lisa Velardo
VP - Bus. Development
Susie Truong
VP - R & D
Johannes Fruehauf
VP - Regulatory Affairs
Pamela Fekete
Browse more venture capital transactions:
Prev: 4/1/2010: Latimer Education venture capital transaction
Next: 4/5/2010: Crimson Hexagon venture capital transaction
Share this article
About Database of VC Transactions
Our team works diligently to record every notable VC transaction. VC investment data records on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs